Less than 30% of FDA-cleared AI devices shared key safety and adverse event data before approval, raising regulatory concerns.
Key Details
- 1A new analysis reviewed FDA approval and recall databases for all AI/ML devices cleared from 1995 to July 2023.
- 2Of 691 devices analyzed, 531 targeted radiology applications.
- 3Fewer than 30% of devices provided data on safety, efficacy, or adverse events prior to approval.
- 4No predefined efficacy or safety reporting standards currently exist for AI/ML devices in the U.S., unlike with pharmaceuticals.
- 5The findings highlight a regulatory gap and call for stricter testing and dedicated approval pathways for AI/ML-based medical devices.
Why It Matters
This research underscores a major gap in regulatory standards and transparency for AI devices in radiology, potentially impacting patient safety and trust. Addressing these concerns could lead to more robust evidence and safer adoption of AI in clinical imaging practice.
Source
Radiology Business
Related News
•Radiology Business
Stanford and Rad Partners Propose Framework for Evaluating Radiology AI Models
Stanford and Rad Partners developed a structured framework for pre-deployment evaluation of radiology AI models to guide purchasing decisions.
•Cardiovascular Business
Radiology Leads in FDA-Cleared Imaging AI Algorithms, Cardiology Surges
Radiology maintains its lead as the specialty with the most FDA-cleared AI algorithms, while cardiology now surpasses 200 cleared tools.
•AuntMinnie
Deep Learning CT Muscle Segmentation Enhances Sarcopenia Detection in COPD
A deep learning model for CT-based 3D pectoralis muscle segmentation outperforms standard 2D techniques in assessing muscle loss among COPD patients.